ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026
Total costs of different lines of treatment in diffuse large B-cell lymphoma in Denmark - a real-world data analysis.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-world patterns of healthcare use, costs, and survival in diffuse large B-cell lymphoma: a nationwide Swedish register study.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundDiffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Cure rate is high after first-line treatment, however, prognosis for relapse/refractory patients remains poor. Multiple treatments to DLBCL have recently been approved, therefore it is important to understand the underlying total costs of the different treatment lines.
objectiveTo investigate the total healthcare costs per line of DLBCL treatment (first-line (1LoT), second-line (2LoT), third-line (3LoT), including best supportive care (BSC)), and to estimate patients' labour market attachment and sickness benefit level.
methodA nationwide real-world registry study covering the Danish DLBCL patients diagnosed 2012-2021 (August) from the National Lymphoma Registry (LYFO). Data were linked with other national registries to estimate the total costs per treatment line. Additionally, costs per line were adjusted to costs per-patient-per-month (PPPM).
results4,159 DLBCL patients were included. Average progression-free time before progression to next LoT or being cured decreased from 2 years (1LoT) to half a year (3LoT + BSC). Average total healthcare costs per patient were estimated to €51,660 (1LoT), €59,094 (2LoT) and €35,808 (3LoT + BSC). Adjusting for progression-free time periods, costs per PPPM increased with later treatment lines. Patients' labour market attachment was in general low, and weeks of sickness benefit increased with later treatment lines.
conclusionThe study suggests that the total costs and weeks of sickness benefit increase with later treatment lines suggesting that more effective first-line treatment options not only have an importance for the patient prognosis but also may have an economic advantage for the healthcare sector and society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.